JR

Janine Rolfe

Cynata Therapeutics Limited | Non-Executive Director
Ms Rolfe joined the Board in September 2022. Ms Rolfe brings more than two decades of legal, governance and management experience across various sectors to the Board. In recent years, Ms Rolfe has transitioned to professional non-executive director roles. Ms Rolfe's last executive role was as General Counsel & Company Secretary for S&P/ASX100 Link Group. Prior to that, Ms Rolfe established governance consultancy, Company Matters, where she served at the helm for over a decade and during a period where stakeholders greatly intensified their expectations of Australian companies' governance practices. Previously, she was a legal counsel and company secretary at Qantas Airways and a solicitor at Mallesons Stephen Jaques (now King & Wood Mallesons).

Companies and Roles

Company
Title
Tenure
Since
CYP
Cynata Therapeutics Limited
  • Non-Executive Director
2yrs, 2mthSep 2022
AMO
Ambertech Limited
  • Non-Executive Director
1yrs, 1mthSep 2023

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
CYP
Cynata Therapeutics Limited
20/11/230116,279578,140N/A
AMO
Ambertech Limited
18/09/230N/AN/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
CYP
Cynata Therapeutics Limited
20/11/23
Issued
220,000$0.120$26,400Issue of options
CYP
Cynata Therapeutics Limited
01/06/23
Issued
116,279$0.215$24,999Placement
CYP
Cynata Therapeutics Limited
01/06/23
Issued
58,140$0.135$7,848Issue of options
CYP
Cynata Therapeutics Limited
23/11/22
Issued
300,000$0.350$105,000Issue of options